• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过大小优化的基因组编码紧凑型腺嘌呤碱基编辑器的单个腺相关病毒在体内实现高效碱基编辑。

Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors.

机构信息

Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.

出版信息

Nat Biomed Eng. 2022 Nov;6(11):1272-1283. doi: 10.1038/s41551-022-00911-4. Epub 2022 Jul 28.

DOI:10.1038/s41551-022-00911-4
PMID:35902773
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9652153/
Abstract

The viral delivery of base editors has been complicated by their size and by the limited packaging capacity of adeno-associated viruses (AAVs). Typically, dual-AAV approaches based on trans-splicing inteins have been used. Here we show that, compared with dual-AAV systems, AAVs with size-optimized genomes incorporating compact adenine base editors (ABEs) enable efficient editing in mice at similar or lower doses. Single-AAV-encoded ABEs retro-orbitally injected in mice led to editing efficiencies in liver (66%), heart (33%) and muscle (22%) tissues that were up to 2.5-fold those of dual-AAV ABE8e, and to a 93% knockdown (on average) of human PCSK9 and of mouse Pcsk9 and Angptl3 in circulation, concomitant with substantial reductions of plasma cholesterol and triglycerides. Moreover, three size-minimized ABE8e variants, each compatible with single-AAV delivery, collectively offer compatibility with protospacer-adjacent motifs for editing approximately 82% of the adenines in the human genome. ABEs encoded within single AAVs will facilitate research and therapeutic applications of base editing by simplifying AAV production and characterization, and by reducing the dose required for the desired level of editing.

摘要

病毒载体的碱基编辑受到其大小和腺相关病毒 (AAV) 有限的包装容量的限制。通常,基于转剪接内含肽的双 AAV 方法被使用。在这里,我们表明,与双 AAV 系统相比,大小优化的基因组中包含紧凑型腺嘌呤碱基编辑器 (ABE) 的 AAV 能够以相似或更低的剂量在小鼠中实现高效编辑。通过逆行注射到小鼠中的单 AAV 编码 ABE 在肝脏(66%)、心脏(33%)和肌肉(22%)组织中的编辑效率高达双 AAV ABE8e 的 2.5 倍,并且对循环中的人 PCSK9 以及小鼠 Pcsk9 和 Angptl3 的平均抑制率达到 93%,同时显著降低了血浆胆固醇和甘油三酯。此外,三个大小最小化的 ABE8e 变体,每个变体都与单 AAV 传递兼容,共同提供与邻近间隔基序的兼容性,可用于编辑人类基因组中约 82%的腺嘌呤。单个 AAV 内编码的 ABE 将通过简化 AAV 的生产和表征,并减少达到所需编辑水平所需的剂量,从而促进碱基编辑的研究和治疗应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa7/9652153/dda8a7a69fc6/41551_2022_911_Fig9_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa7/9652153/9a76405fe3e3/41551_2022_911_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa7/9652153/9d8d4bcabf5a/41551_2022_911_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa7/9652153/c7fa08ff8cef/41551_2022_911_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa7/9652153/3978749d99cd/41551_2022_911_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa7/9652153/5cfef705ba1e/41551_2022_911_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa7/9652153/d9d28a72e274/41551_2022_911_Fig6_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa7/9652153/405b091e01c5/41551_2022_911_Fig7_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa7/9652153/1ee0dfefaf28/41551_2022_911_Fig8_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa7/9652153/dda8a7a69fc6/41551_2022_911_Fig9_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa7/9652153/9a76405fe3e3/41551_2022_911_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa7/9652153/9d8d4bcabf5a/41551_2022_911_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa7/9652153/c7fa08ff8cef/41551_2022_911_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa7/9652153/3978749d99cd/41551_2022_911_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa7/9652153/5cfef705ba1e/41551_2022_911_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa7/9652153/d9d28a72e274/41551_2022_911_Fig6_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa7/9652153/405b091e01c5/41551_2022_911_Fig7_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa7/9652153/1ee0dfefaf28/41551_2022_911_Fig8_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa7/9652153/dda8a7a69fc6/41551_2022_911_Fig9_ESM.jpg

相似文献

1
Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors.通过大小优化的基因组编码紧凑型腺嘌呤碱基编辑器的单个腺相关病毒在体内实现高效碱基编辑。
Nat Biomed Eng. 2022 Nov;6(11):1272-1283. doi: 10.1038/s41551-022-00911-4. Epub 2022 Jul 28.
2
A new compact adenine base editor generated through deletion of HNH and REC2 domain of SpCas9.通过删除 SpCas9 的 HNH 和 REC2 结构域生成的新型紧凑型腺嘌呤碱基编辑器。
BMC Biol. 2023 Jul 11;21(1):155. doi: 10.1186/s12915-023-01644-9.
3
Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.腺相关病毒介导的小鼠大脑、肝脏、视网膜、心脏和骨骼肌中的胞嘧啶和腺嘌呤碱基编辑。
Nat Biomed Eng. 2020 Jan;4(1):97-110. doi: 10.1038/s41551-019-0501-5. Epub 2020 Jan 14.
4
Compact Cje3Cas9 for Efficient Genome Editing and Adenine Base Editing.紧凑型 Cje3Cas9 用于高效基因组编辑和腺嘌呤碱基编辑。
CRISPR J. 2022 Jun;5(3):472-486. doi: 10.1089/crispr.2021.0143.
5
Adenine Base Editing with a Single Adeno-Associated Virus Vector.使用单一腺相关病毒载体的腺嘌呤碱基编辑
GEN Biotechnol. 2022 Jun 1;1(3):285-299. doi: 10.1089/genbio.2022.0015. Epub 2022 Jun 14.
6
A Compact, High-Accuracy Cas9 with a Dinucleotide PAM for In Vivo Genome Editing.一种紧凑型、高精度的 Cas9,带有双核苷酸 PAM,用于体内基因组编辑。
Mol Cell. 2019 Feb 21;73(4):714-726.e4. doi: 10.1016/j.molcel.2018.12.003. Epub 2018 Dec 20.
7
A truncated reverse transcriptase enhances prime editing by split AAV vectors.截短的逆转录酶增强了分裂 AAV 载体的 Prime 编辑。
Mol Ther. 2022 Sep 7;30(9):2942-2951. doi: 10.1016/j.ymthe.2022.07.001. Epub 2022 Jul 8.
8
Advances in base editing with an emphasis on an AAV-based strategy.碱基编辑技术的进展,重点介绍基于 AAV 的策略。
Methods. 2021 Oct;194:56-64. doi: 10.1016/j.ymeth.2021.03.015. Epub 2021 Mar 25.
9
Versatile and efficient in vivo genome editing with compact Streptococcus pasteurianus Cas9.利用紧凑型巴氏链球菌 Cas9 在体内进行多功能且高效的基因组编辑。
Mol Ther. 2022 Jan 5;30(1):256-267. doi: 10.1016/j.ymthe.2021.06.013. Epub 2021 Jun 24.
10
In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels.体内编辑灵长类动物 PCSK9 的腺嘌呤碱基可降低 LDL 胆固醇水平。
Nat Biotechnol. 2021 Aug;39(8):949-957. doi: 10.1038/s41587-021-00933-4. Epub 2021 May 19.

引用本文的文献

1
Treatment of a severe vascular disease using a bespoke CRISPR-Cas9 base editor in mice.在小鼠中使用定制的CRISPR-Cas9碱基编辑器治疗严重血管疾病。
Nat Biomed Eng. 2025 Sep 11. doi: 10.1038/s41551-025-01499-1.
2
Gene editing for collagen disorders: current advances and future perspectives.用于胶原蛋白疾病的基因编辑:当前进展与未来展望。
Gene Ther. 2025 Aug 11. doi: 10.1038/s41434-025-00560-7.
3
GFP-on mouse model for interrogation of in vivo gene editing.用于体内基因编辑检测的绿色荧光蛋白开启型小鼠模型。

本文引用的文献

1
Adenine Base Editing with a Single Adeno-Associated Virus Vector.使用单一腺相关病毒载体的腺嘌呤碱基编辑
GEN Biotechnol. 2022 Jun 1;1(3):285-299. doi: 10.1089/genbio.2022.0015. Epub 2022 Jun 14.
2
Engineered Campylobacter jejuni Cas9 variant with enhanced activity and broader targeting range.具有增强活性和更广泛靶向范围的工程化空肠弯曲菌Cas9变体。
Commun Biol. 2022 Mar 8;5(1):211. doi: 10.1038/s42003-022-03149-7.
3
Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins.工程病毒样颗粒用于高效体内递送治疗性蛋白。
Nat Commun. 2025 Jul 31;16(1):7017. doi: 10.1038/s41467-025-61449-y.
4
A Compact Base Editor Rescues AATD-associated Liver and Lung Disease in Mouse Models.一种紧凑型碱基编辑器可挽救小鼠模型中与α-1抗胰蛋白酶缺乏症相关的肝脏和肺部疾病。
bioRxiv. 2025 May 9:2025.05.07.652636. doi: 10.1101/2025.05.07.652636.
5
Advancements in CRISPR/Cas systems for disease treatment.用于疾病治疗的CRISPR/Cas系统的进展。
Acta Pharm Sin B. 2025 Jun;15(6):2818-2844. doi: 10.1016/j.apsb.2025.05.007. Epub 2025 May 17.
6
High-precision cytosine base editors by evolving nucleic-acid-recognition hotspots in deaminase.通过进化脱氨酶中的核酸识别热点构建高精度胞嘧啶碱基编辑器。
Nat Biotechnol. 2025 Jul 7. doi: 10.1038/s41587-025-02678-w.
7
CNS-targeted base editing of the major late-onset Tay-Sachs mutation alleviates disease in mice.对主要迟发性泰-萨克斯突变进行中枢神经系统靶向碱基编辑可缓解小鼠疾病。
J Clin Invest. 2025 Jun 17;135(16). doi: 10.1172/JCI183434.
8
Gene editing therapy as a therapeutic approach for cardiovascular diseases in animal models: A scoping review.基因编辑疗法作为动物模型中心血管疾病的一种治疗方法:一项范围综述。
PLoS One. 2025 Jun 4;20(6):e0325330. doi: 10.1371/journal.pone.0325330. eCollection 2025.
9
Base editing of trinucleotide repeats that cause Huntington's disease and Friedreich's ataxia reduces somatic repeat expansions in patient cells and in mice.对导致亨廷顿舞蹈症和弗里德赖希共济失调的三核苷酸重复序列进行碱基编辑可减少患者细胞和小鼠体内的体细胞重复序列扩增。
Nat Genet. 2025 May 26. doi: 10.1038/s41588-025-02172-8.
10
Engineering adeno-associated viral vectors for CRISPR/Cas based in vivo therapeutic genome editing.工程化腺相关病毒载体用于基于CRISPR/Cas的体内治疗性基因组编辑
Biomaterials. 2025 Oct;321:123314. doi: 10.1016/j.biomaterials.2025.123314. Epub 2025 Apr 2.
Cell. 2022 Jan 20;185(2):250-265.e16. doi: 10.1016/j.cell.2021.12.021. Epub 2022 Jan 11.
4
Gene therapy community grapples with toxicity issues, as pipeline matures.随着基因治疗产品线的成熟,该领域正努力应对毒性问题。
Nat Rev Drug Discov. 2021 Nov;20(11):804-805. doi: 10.1038/d41573-021-00164-x.
5
In vivo somatic cell base editing and prime editing.体内体细胞碱基编辑和先导编辑。
Mol Ther. 2021 Nov 3;29(11):3107-3124. doi: 10.1016/j.ymthe.2021.09.002. Epub 2021 Sep 10.
6
CRISPR-Cas9 globin editing can induce megabase-scale copy-neutral losses of heterozygosity in hematopoietic cells.CRISPR-Cas9 基因编辑可诱导造血细胞内中靶基因座的大片段拷贝数中性缺失。
Nat Commun. 2021 Aug 13;12(1):4922. doi: 10.1038/s41467-021-25190-6.
7
Regulated control of gene therapies by drug-induced splicing.药物诱导剪接调控基因治疗。
Nature. 2021 Aug;596(7871):291-295. doi: 10.1038/s41586-021-03770-2. Epub 2021 Jul 28.
8
Efficient precise in vivo base editing in adult dystrophic mice.在成年肌肉萎缩症小鼠中高效精确的体内碱基编辑。
Nat Commun. 2021 Jun 17;12(1):3719. doi: 10.1038/s41467-021-23996-y.
9
In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels.体内编辑灵长类动物 PCSK9 的腺嘌呤碱基可降低 LDL 胆固醇水平。
Nat Biotechnol. 2021 Aug;39(8):949-957. doi: 10.1038/s41587-021-00933-4. Epub 2021 May 19.
10
In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates.体内 CRISPR 碱基编辑持久降低灵长类动物的 PCSK9 胆固醇。
Nature. 2021 May;593(7859):429-434. doi: 10.1038/s41586-021-03534-y. Epub 2021 May 19.